Administration of synthetic agonists of PPARG increases plas...
| created | [InstanceEdit:9856210] Orlic-Milacic, Marija, 2023-12-13 |
| dbId | 9856212 |
| displayName | Administration of synthetic agonists of PPARG increases plas... |
| modified | [InstanceEdit:9907643] Orlic-Milacic, Marija, 2024-04-15 |
| schemaClass | Summation |
| text | Administration of synthetic agonists of PPARG increases plasma ADIPOQ protein levels in both insulin resistant humans and mice (Maeda et al. 2001). In cultured mouse 3T3-L1 white preadipocytes, PPARG synthetic agonists enhance mRNA transcription and secretion of Adipoq protein (Maeda et al. 2001). Treatment of mouse white preadipocyte cell line 3T3-L1 with PPARG agonists results in increased Adipoq mRNA levels (Bhalla et al. 2011). In obese diabetic mice chronically treated with PPARG synthetic agonists (11-day treatment window), mean plasma Adipoq protein levels increase (Combs et al. 2002). Expression of Adipoq is significantly down-regulated in white adipose tissue (WAT) of Kmt2c (Mll3) delta/delta mice that express a H3K4 methyltransferase-inactive Kmt2c mutant (Lee et al. 2008). Expression of the Adipoq gene is severely reduced in differentiating mouse brown preadipocytes expressing histone H3.3 K4M mutant or Kmt2c and Kmt2d (Mll4) with deleted SET domains (Jang et al. 2019: RNA-seq, supplementary information). |
© 2026 Reactome
